ROCKY HILL, Conn., Oct. 28, 2021 /PRNewswire-PRWeb/ -- Lumeda Inc., a medical technology company advancing photodynamic therapy (PDT) as an intraoperative adjuvant treatment for patients during lung cancer surgery, today announced that its management team has been included in the Hartford Business Journal (HBJ) second annual Power 25 Health Care list, featuring leaders who are significantly impacting the healthcare industry and public health. Chosen and ranked by the HBJ news team, the Power 25 Health Care recognizes individuals who use their power to have an outsized impact on the community.
"Along with the two Lumeda founders, Trevor MacDougall and Paul Sanders, I am honored to be included among an impressive group of healthcare leaders, chosen by HBJ for the Power 25 Health Care list," said Lumeda CEO, Sandy Zinke. "Trevor and Paul have worked together for over 30 years, since meeting at 3M, and have a history of developing innovative and reliable technical solutions to engineering challenges. I'm thrilled to be working with them as they apply their talents and entrepreneurial approach to the healthcare field. I'm confident we can help physicians improve quality of life and survival for people suffering from lung cancer."
In just 18 months, the Lumeda team has developed and shipped its first preclinical system to its institutional partner, Roswell Park Comprehensive Cancer Center. The company expects to ship its next unit, to be used in two approved human clinical studies, to Roswell Park in early 2022.
Lumeda is advancing a medical device innovation, demonstrated by Roswell Park, for applying photodynamic therapy (PDT) to treat lung malignancies. PDT is a two-stage cancer treatment that involves a photosensitizer drug that preferentially collects within cancer cells and then produces cell death upon light activation. While PDT has been shown to significantly improve patient outcomes, the adoption of PDT in treating lung cancer has been limited due to its complicated, time-consuming, and unreliable method of administration. Lumeda's breakthrough DigiLum™ system addresses these shortcomings, enabling thoracic surgeons to apply PDT in a short, simplified intraoperative procedure added to standard-of-care to improve patient response to immunotherapy and reduce disease recurrence. Two Phase I clinical studies to evaluate the safety and effectiveness of PDT using the company's product have recently opened at Roswell Park. Patients are actively being recruited for participation in the trials.
About Lumeda:
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit lumedainc.com.
Media Contact
Paul E. Sanders, Lumeda, +1 860 614-0849, [email protected]
SOURCE Lumeda
Share this article